September 21, 2025 – Jiao Mingming, General Manager of Zhejiang Tianyuan Biotechnology Co., Ltd., and Dr. Liu Guangcheng, Director of the Cell Laboratory, were invited to attend the "2025 Ningbo Cytopathology Training Course: New Theories, Knowledge, and Technologies," organized by the Ningbo Clinical Pathology Quality Control Center.

      At the training course, Dr. Liu Guangcheng, as an invited speaker, delivered an insightful presentation titled "Improved Cultivation Methods to Enhance the Application Value of Primary Cells." Leveraging his profound research background and extensive practical experience, Dr. Liu elaborated on Tianyuan Bio's innovative achievements in cell culture technology. He highlighted how optimized cultivation methods significantly improve the viability, stability, and application value of primary cells, providing higher-quality and more reliable cell resources for cytopathology research, clinical studies, and medical applications.

      Dr. Liu's presentation garnered widespread attention and sparked lively discussions among the attending professionals. Participants highly commended Tianyuan Bio's technical expertise and innovative capabilities in the field of cell culture, unanimously agreeing that the company's achievements not only advance the development of cytopathology but also offer new insights and methods for clinical diagnosis and treatment.

      During the event, General Manager Jiao Mingming emphasized that Tianyuan Bio remains committed to the research, development, and innovation of cell technologies, actively engaging in collaboration and exchange with professional institutions and experts in the industry. He noted that participating in the training course and sharing the company's scientific achievements not only demonstrated Tianyuan Bio's research capabilities but also established a communication bridge with professionals in the field of pathological diagnosis.

      Through this event, Tianyuan Bio has forged closer ties with professional institutions such as the Ningbo Clinical Pathology Diagnosis Center, laying a solid foundation for future collaborations in cytopathology technology research and clinical application translation. Moving forward, Tianyuan Bio will continue to uphold its philosophy of innovation-driven development, constantly enhancing its research capabilities to contribute further to the advancement of the cytopathology industry.

Zhejiang Tianyuan Biotechnology Co., Ltd., founded in 2017, is a national high-tech enterprise dedicated to cell research, development, production, operation, and services. It boasts valuable resource banks, including an HLA Umbilical Cord Matching Library, iPS Seed Cell Bank, and Cancer Cell Bank. The company is the drafting unit for the National Health Commission's association standard for immune function assessment methods. In collaboration with the National Health Commission's Research Institute, it has established a Joint Laboratory for Metabolic Immunity Monitoring. Additionally, it serves as the Ningbo Storage Center for the National Stem Cell Transformation Resource Bank and the Achievement Transformation Center for the National Health Commission's Research Institute, among other key research and service platforms.